CSIMarket
 
Pfizer Inc  (PFE)
 

News




European Commission Approves Pfizer*s PREVENAR 20, Boosting Protection Against Pneumococcal Disease in Infants and Children

Pfizer*s ABRYSVO Vaccine Shows Promising Efficacy Against Respiratory Syncytial Virus in Older Adults, Amidst Adverse Market Conditions

Pfizer*s VELSIPITY Receives European Commission Approval for Patients with Moderately to Severely Active Ulcerative Colitis, but Challenges Remain for Pfizer Inc.

Carrick Therapeutics Initiates Phase 1b/2 Clinical Trial Assessing Samuraciclib and Vepdegestrant Combination Therapy in Advanced Breast Cancer Patients

Arvinas and Pfizer*s Vepdegestrant Receives FDA Fast Track Designation for Promising Treatment of ER+/HER2- Metastatic Breast Cancer

European Medicines Agency Validates Combination Therapy for Advanced Bladder Cancer Treatment: A Glimpse into Pfizer Inc.*s Challenges and New Treatment Approaches

FDA Accepts TIVDAK sBLA for Priority Review Amid Pfizer*s Corporate Revenue Shifts and Market Challenges

Pfizer Pioneers Groundbreaking Prostate Cancer Therapy: Talazoparib Receives European Approval in Combination with Xtandi

Pfizer Showcases Resilient Growth with Impressive Sales and Cost of Sales Surge in Q3, while Prepping Investors for Exciting Q4 2023 Performance Report

Pfizer*s Revenue Decline Amid Cancer Treatment Advancements Raises Concerns

Pfizer Inc. Faces Financial Challenges: Revenue Crumbles in Fiscal Fourth Quarter of 2023

PFE*s Revenue Takes a Shocking Plunge: A Defining Moment for Pfizer Inc*s Fiscal Period Ending October 01, 2023

Pfizer Inc Announces Substantial Revenue Decline Throughout Sophisticated Fiscal Quarter Ending July 02, 2023

Pfizer Inc*s Financial Slump Continues: Profits Plunge and Revenue Falters in First Quarter of 2023

Outstanding Earnings per Share Increase by 59.3 % at the company amid the first quarter of 2022

on the higher pace

revenue receded by -6.043 %, at PFE over the financial time-frame closing Oct 02 2022

The Major Pharmaceutical Preparations company declared a top-line surge by very vibrant 87.019%, during the most recent fiscal period









Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com